You are here

Acceleron

A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

Endpoints

beta thalassemia

Flag link:

Acceleron blood disease drug hits goal in pivotal clinical trial

Acceleron blood disease drug hits goal in pivotal clinical trial

Stat

clinical trials

myelodysplastic syndrome

Flag link:

Billions of Dollars on the Line for Celgene With These 3 Small Biotechs

Billions of Dollars on the Line for Celgene With These 3 Small Biotechs

Motley Fool

Juno Therapeutics

Flag link:

Phase II Fail Prompts Acceleron to Discontinue Development of Renal Cell Carcinoma Drug

Phase II Fail Prompts Acceleron to Discontinue Development of Renal Cell Carcinoma Drug

Xtalks

renal cell carcinoma

clinical trials

Flag link:

Acceleron dumps dalantercept after kidney cancer trial fail

Acceleron dumps dalantercept after kidney cancer trial fail

Fierce Biotech

clinical trials

Flag link:

The Most Important Keys To Celgene's Pipeline

The Most Important Keys To Celgene's Pipeline

Seeking Alpha

Juno Therapeutics

Flag link:

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Yahoo

myelodysplastic syndromes

Flag link:

Acceleron Pharma Has 2 Drug Candidates That Could Become Blockbusters

Acceleron Pharma Has 2 Drug Candidates That Could Become Blockbusters

Seeking Alpha

Flag link:

A pair of Celgene partners gets on the FDA fast track

A pair of Celgene partners gets on the FDA fast track

Fierce Biotech

beta-thalassemia

Agios Pharmaceuticals

Flag link:

Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline

Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline

TheStreet.com

Flag link:

3 Biggest Biotech Crashes in March

3 Biggest Biotech Crashes in March

Motley Fool

Celldex Therapeutics

NewLink Genetics

Flag link:

[video]Biotech CEO looks down the pipeline for growth

[video]Biotech CEO looks down the pipeline for growth

CNBC

Flag link:

The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron

The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron

TheStreet.com

Sangamo BioSciences

Flag link:

Acceleron, Celgene Vs. Amgen In The Anemia Drug Race

Acceleron, Celgene Vs. Amgen In The Anemia Drug Race

Seeking Alpha

Flag link:

ASH Conference: 3 Companies To Watch

ASH Conference: 3 Companies To Watch

Seeking Alpha

Stemline Therapeutics

Flag link:

Acceleron: A Small Biotech Preparing To Supply Big Markets

Acceleron: A Small Biotech Preparing To Supply Big Markets

Seeking Alpha

Flag link:

Acceleron Pharma - Successful Cancer Research IPO

Acceleron Pharma - Successful Cancer Research IPO

Seeking Alpha

Flag link:

[video]Biotech IPOs With Big Partners

[video]Biotech IPOs With Big Partners

TheStreet.com

Bind Therapeutics

Fate Therapeutics

Flag link:

Acceleron Receives Two FDA Orphan Designations for ACE-536

Acceleron Receives Two FDA Orphan Designations for ACE-536

Yahoo

beta-thalassemia

myelodysplastic syndromes

Flag link:

Pages